Literature DB >> 11713103

What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge.

E D Chan1, J Chan, N W Schluger.   

Abstract

The production of reactive oxygen intermediates and reactive nitrogen intermediates by innate immune cells is considered to be an effective host-defense mechanism against microbial pathogens. In the murine model of tuberculosis (TB), nitric oxide (NO) plays an essential role in the killing of Mycobacterium tuberculosis by mononuclear phagocytes. For example, in the mouse strain with a genetic disruption for inducible NO synthase (iNOS-/-), infection with M. tuberculosis is associated with a significantly higher risk of dissemination and mortality. Although more controversial in humans, there is a growing body of evidence that NO produced by TB-infected macrophages and by epithelial cells also has antimycobacterial effects against M. tuberculosis. The precise mechanism(s) by which NO and other reactive nitrogen species antagonize M. tuberculosis is not known, but may involve disruption of bacterial DNA, proteins, signaling, and/or induction of apoptosis of macrophages that harbor mycobacteria. In addition to cytokines such as tumor necrosis factor-alpha and interleukin 1-beta, mycobacterial cell wall components such as lipoarabinomannan and 19 kD lipoprotein, along with the T-cell-derived interferon-gamma, may also induce NO expression. In a Darwinian fashion, it also appears that certain strains of M. tuberculosis have evolved strategies to combat the toxic effects of NO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713103     DOI: 10.1165/ajrcmb.25.5.4487

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  80 in total

1.  Inhibitory effect of NO-releasing ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survival.

Authors:  R Ciccone; F Mariani; A Cavone; T Persichini; G Venturini; E Ongini; V Colizzi; M Colasanti
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress.

Authors:  Tatiana D Sirakova; Vinod S Dubey; Chirajyoti Deb; Jaiyanth Daniel; Tatiana A Korotkova; Bassam Abomoelak; Pappachan E Kolattukudy
Journal:  Microbiology (Reading)       Date:  2006-09       Impact factor: 2.777

3.  Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  Richard Long; Richard Jones; James Talbot; Irvin Mayers; James Barrie; Michael Hoskinson; Bruce Light
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Hila Ovadiah; Inbar Azoulay; Shai Ashkenazi
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Reaction of Mycobacterium tuberculosis cytochrome P450 enzymes with nitric oxide.

Authors:  Hugues Ouellet; Jérôme Lang; Manon Couture; Paul R Ortiz de Montellano
Journal:  Biochemistry       Date:  2009-02-10       Impact factor: 3.162

6.  A role for IL-18 in protective immunity against Mycobacterium tuberculosis.

Authors:  Bianca E Schneider; Daniel Korbel; Kristine Hagens; Markus Koch; Bärbel Raupach; Jana Enders; Stefan H E Kaufmann; Hans-Willi Mittrücker; Ulrich E Schaible
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

7.  Sphingosine kinase-1 (SphK-1) regulates Mycobacterium smegmatis infection in macrophages.

Authors:  Hridayesh Prakash; Anja Lüth; Natalia Grinkina; Daniela Holzer; Raj Wadgaonkar; Alexis Perez Gonzalez; Elsa Anes; Burkhard Kleuser
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

8.  The SPRY domain-containing SOCS box protein SPSB2 targets iNOS for proteasomal degradation.

Authors:  Zhihe Kuang; Rowena S Lewis; Joan M Curtis; Yifan Zhan; Bernadette M Saunders; Jeffrey J Babon; Tatiana B Kolesnik; Andrew Low; Seth L Masters; Tracy A Willson; Lukasz Kedzierski; Shenggen Yao; Emanuela Handman; Raymond S Norton; Sandra E Nicholson
Journal:  J Cell Biol       Date:  2010-07-05       Impact factor: 10.539

9.  Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages.

Authors:  Nadia L Ferrer; Ana B Gomez; Olivier Neyrolles; Brigitte Gicquel; Carlos Martin
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

10.  CD36 deficiency attenuates experimental mycobacterial infection.

Authors:  Michael Hawkes; Xiaoming Li; Maryanne Crockett; Angelina Diassiti; Constance Finney; Gundula Min-Oo; W Conrad Liles; Jun Liu; Kevin C Kain
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.